Last reviewed · How we verify
TMC207
At a glance
| Generic name | TMC207 |
|---|---|
| Also known as | bedaquiline, R207910 |
| Sponsor | Global Alliance for TB Drug Development |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2, PHASE3)
- Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB (PHASE2)
- Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PHASE2, PHASE3)
- Short-course Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2, PHASE3)
- A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB (PHASE3)
- Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB (PHASE2)
- Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis (PHASE2)
- Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TMC207 CI brief — competitive landscape report
- TMC207 updates RSS · CI watch RSS
- Global Alliance for TB Drug Development portfolio CI